Onboarding steps made convenient with PONVORY®1-4

Person and child playing in the water

Unlike any other S1P modulator, PONVORY® has the unique combination of1-4:

No known food restrictions icon

No known food

No known drug interactions icon

No known drug
with SSRIs

Before initiation of treatment with PONVORY®, assess the following based on individual patient needs: complete blood count, cardiac evaluation, liver function tests, ophthalmic evaluation, current or prior medications with immune system effects, and vaccinations.1

S1P = sphingosine-1-phosphate; SSRI = selective serotonin reuptake inhibitor.

See the pretests and assessments required before initiating PONVORY® >

For select patients, first dose monitoring is recommended1

Because initiation of PONVORY® treatment results in a decrease in heart rate (HR), first dose, 4-hour monitoring is recommended for patients with1:

  • Sinus bradycardia (HR <55 beats per minute [bpm])
  • First- or second-degree atrioventricular (AV) block (Mobitz type I)
  • History of myocardial infarction or heart failure occurring >6 months prior to treatment initiation and in stable condition

For select patients who require first dose monitoring1:

Pill and water bottle icon

ADMINISTER the first dose of PONVORY® in a setting where resources to appropriately manage symptomatic bradycardia are available

Monitor patients icon

MONITOR patients for 4 hours after the first dose for signs and symptoms of bradycardia with a minimum of hourly pulse and blood pressure measurements

ECG icon

OBTAIN an ECG in these patients prior to dosing and at the end of the 4-hour observation period

For more detailed information about first dose monitoring,
please see Section 2.3 in the PONVORY® full Prescribing Information.

Before initiation of treatment with PONVORY®, assess the following1:

List of common pretests and assessments

AV = atrioventricular; CBC = complete blood count; ECG = electrocardiogram; MS = multiple sclerosis; VZV = varicella-zoster virus.